High-dose flu shot linked to 55% lower Alzheimer's risk in older adults
A study of nearly 200,000 adults 65+ found high-dose flu vaccine recipients had about 55% lower Alzheimer's risk, versus roughly 40% with standard-dose shots.
Summary
Brain health in older adults may be tied to which flu shot they receive. Researchers at UTHealth Houston analyzed records from nearly 200,000 adults aged 65 and older and found that those given the high-dose influenza vaccine had about a 55% lower risk of developing Alzheimer's disease. That compares with a roughly 40% reduction previously linked to the standard-dose vaccine. High-dose shots contain four times as much flu antigen and are already recommended by the CDC for seniors because aging immune systems respond less strongly to vaccines. The study, published in Neurology, grew out of the same team's earlier work linking flu vaccination to lower Alzheimer's risk. The findings are associations from observational data, so they do not prove the vaccine prevents dementia. Still, they add to growing interest in how immune health and infection protection shape brain aging.
Detailed Summary
Alzheimer's disease is the leading cause of dementia. In 2025, more than 7 million Americans aged 65 and older were living with it, about 1 in 9 in that age group, and that number is projected to more than double by 2050. Any accessible strategy that might lower risk therefore deserves attention.
Researchers at UTHealth Houston, led by neurologist Paul Schulz, MD, analyzed nearly 200,000 adults aged 65 and older. Those who received a high-dose influenza vaccine had a nearly 55% lower risk of developing Alzheimer's than comparison groups. A 2022 study by the same team had linked standard-dose flu vaccination to about a 40% lower risk. The results were published in the journal Neurology.
The question arose when local public health officials, who had seen the earlier vaccine research, asked whether dose made a difference. High-dose vaccines contain four times the influenza antigen of standard shots. The CDC already recommends them as a preferred option for adults 65 and older, since immune function declines with age (immunosenescence) and flu is especially dangerous for seniors.
The practical implication is modest but notable. Older adults are already advised to get a yearly flu shot, and the high-dose version is a preferred choice for protecting against influenza itself. This research suggests a possible added brain benefit, which fits with theories that infections, inflammation and immune responses influence neurodegeneration. A stronger immune response to vaccination might also reflect or support healthier immune aging.
Caveats matter. This is an observational study, so it shows association rather than causation. People who choose or are offered high-dose vaccines may differ in health habits, access to care or baseline risk, and residual confounding is possible. The mechanism is unknown. Readers should not treat a flu shot as an Alzheimer's prevention therapy, but should see it as one reasonable part of a broader healthy-aging strategy, and discuss vaccine options with their clinician.
Key Findings
- Adults 65+ who got high-dose flu vaccine had a nearly 55% lower Alzheimer's risk in a cohort of almost 200,000.
- Standard-dose flu vaccination was previously associated with about a 40% lower Alzheimer's risk in the team's 2022 study.
- High-dose vaccines contain four times the antigen and are a CDC-preferred option for adults aged 65 and older.
- The study is observational, so it shows association and cannot prove the vaccine prevents Alzheimer's.
- Findings appeared in Neurology and support links between immune protection and brain aging.
Methodology
This is a university press release summarized by ScienceDaily, describing an observational cohort study of nearly 200,000 adults aged 65+ published in Neurology. The source is credible (UTHealth Houston, peer-reviewed journal), but the evidence is associative rather than from a randomized trial.
Study Limitations
The excerpt is truncated and lacks details on study design, confounder adjustment, follow-up length and absolute risk. Observational data may reflect healthy-user bias or differences in access to care. Check the original Neurology paper for methods and effect sizes before drawing conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: